Polivy 30 mg powder for concentrate for solution for infusion. clinical trials
3 indexed studies · 0 currently recruiting
- AuthorisedTherapeutic exploratory (Phase II)
A phase II efficacy and safety study of cell-free circulating tumor DNA-guided commencement of second-line treatment in patients with DLBCL/HGBCL relapse
This study looks at new ways to decide when to start a second treatment for certain types of lymphoma, using a blood test. It aims to see if this approach is safe and effective in helping patients.
For: Diffuse large B-cell lymphomas (DLBCL · Diffuse large B-cell lymphoma) and aggressive B-cell lymphomas (HGBCL · High-grade B-cell lymphoma) originate from mature B-cells at various stages of terminal differentiationPoland - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase I/II Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Patients with Diffuse Large B-Cell Lymphoma following First-Line Immunochemotherapy and as Monotherapy or In Combination With Polatuzumab Vedotin in Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma
This study is looking at new ways to treat Diffuse Large B-Cell Lymphoma (DLBCL), a type of blood cancer. Researchers are testing a drug called mosunetuzumab, by itself or with another drug, polatuzumab vedotin. The aim is to see how well these treatments work and if they are safe.
For: Diffuse Large B-Cell Lymphoma (DLBCL)Spain · Poland - Ongoing, recruitingTherapeutic exploratory (Phase II)
Efficacy of Polatuzumab, Bendamustine and Rituximab in patients with relapsed/refractory mantle cell lymphoma- A single center phase II trial
This study looks at a new combination of medicines (MabThera, Polivy, and Bendamustin) for people with a type of blood cancer called mantle cell lymphoma that has come back or not responded to previous treatments. It aims to see how safe and effective this treatment is.
For: Mantle cell lymphomaAustria